Repligen Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7599161095
USD
165.76
0.74 (0.45%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Repligen Corp. stock-summary
stock-summary
Repligen Corp.
Pharmaceuticals & Biotechnology
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Company Coordinates stock-summary
Company Details
41 Seyon St Bldg 1 Ste 100 , WALTHAM MA : 02453-8348
stock-summary
Tel: 1 781 4499560
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 121 Schemes (55.53%)

Foreign Institutions

Held by 260 Foreign Institutions (14.67%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Karen Dawes
Independent Chairperson of the Board
Mr. Anthony Hunt
President, Chief Executive Officer, Director
Ms. Carrie Eglinton
Director
Mr. Nicolas Barthelemy
Independent Director
Mr. Rohin Mhatre
Independent Director
Mr. Glenn Muir
Independent Director
Mr. Thomas Ryan
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
182 Million
(Quarterly Results - Jun 2025)
Net Profit:
15 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6,790 Million (Small Cap)

stock-summary
P/E

210.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.08

stock-summary
Return on Equity

1.82%

stock-summary
Price to Book

3.29